Archives

Major Depressive Disorder (MDD) In Chronic Kidney Disease (CKD)
About This Event
Major Depressive Disorder (MDD) In Chronic Kidney Disease (CKD)
Major depressive disorder affects more than 260 million people worldwide.1 The reported prevalence of depression in patients with chronic kidney disease ranges from 20-65%.2 This presentation provides an overview of both MDD and CKD and discusses their overlap of symptomology.
1. World Health Organization. Fact Sheet on Depression. (2012) https://www.who.int/health-topics/depression#tab=tab_1
2. Teles F et al. Clinics (Sao Paulo). 2014 ;69(3):198-202.
SILO Elevated Cuisine – 1604
San Antonio, Texas 78232 United States + Google Map

Molly Jansen, PhD
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Dr Molly Jansen is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. covering South Texas. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem, NC. While in graduate school, Molly worked as a Business Development Intern at Wake Forest Innovations, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka, Molly worked at Reata Pharmaceuticals, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology, neurology, and pulmonary, which is where she developed her passion for rare disease.

Dennis Pabis, PharmD, BCPP (OPDC)
Otsuka Pharmaceutical Development & Commercialization, Inc.*
*Drs Jansen and Pabis are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).